Viktor Magdolen

List of Publications by Year
in descending order

72	1,648	257450 24	330143 37
papers	citations	h-index	g-index

72	72	72	2162
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer. British Journal of Cancer, 2022, 126, 1470-1480.	6.4	23
2	tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression. Cancers, 2022, 14, 24.	3.7	25
3	Epigenetic modulators combination with chemotherapy in breast cancer cells. Cell Biochemistry and Function, 2021, 39, 571-583.	2.9	2
4	The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Lowâ€“Expressing CancerIn VitroandIn Vivo. Cancer Immunology Research, 2021, 9, 779-789.	3.4	10
5	Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1. Nature Chemical Biology, 2021, 17, 776-783.	8.0	17
6	The prognostic and diagnostic potential of kallikrein-related peptidases in ovarian cancer. Expert Review of Molecular Diagnostics, 2021, 21, 535-545.	3.1	3
7	Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 3969.	3.7	11
8	PITX2 DNA-Methylation: Predictive versus Prognostic Value for Anthracycline-Based Chemotherapy in Triple-Negative Breast Cancer Patients. Breast Care, 2021, 16, 523-531.	1.4	3
9	Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer. American Journal of Translational Research (discontinued), 2021, 13, 1594-1606.	0.0	0
10	Rab31-dependent regulation of transforming growth factor ÃŸ expression in breast cancer cells. Molecular Medicine, 2021, 27, 158.	4.4	3
11	miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study. Carcinogenesis, 2020, 41, 442-451.	2.8	10
12	Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer. Journal of Ovarian Research, 2020, 13, 125.	3.0	3
13	KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer. Cancers, 2020, 12, 3501.	3.7	5
14	Intrathecal antibodies against herpes simplex virus are associated with tau pathology in humans with Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e041938.	0.8	1
15	miR â€181a overexpression predicts the poor treatment response and earlyâ€progression of serous ovarian cancer patients. International Journal of Cancer, 2020, 147, 3560-3573.	5.1	7
16	Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients. Molecular Medicine, 2020, 26, 19.	4.4	8
17	High levels of KLK7 protein expression are related to a favorable prognosis in triple-negative breast cancer patients. American Journal of Cancer Research, 2020, 10, 1785-1792.	1.4	0
18	Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer. BMC Cancer, 2019, 19, 696.	2.6	7

#	Article	IF	Citations
19	Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimerâ€™s disease and associated with CSF-TAU and FDG-PET. Translational Neurodegeneration, 2019, 8, 25.	8.0	11
20	Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors. Cancer and Metastasis Reviews, 2019, 38, 417-430.	5.9	27
21	Surface loops of trypsin-like serine proteases as determinants of function. Biochimie, 2019, 166, 52-76.	2.6	46
22	Integration of Two In-depth Quantitative Proteomics Approaches Determines the Kallikrein-related Peptidase 7 (KLK7) Degradome in Ovarian Cancer Cell Secretome. Molecular and Cellular Proteomics, 2019, 18, 818a-836.	3.8	16
23	Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients. PLoS ONE, 2019, 14, e0212968.	2.5	13
24	PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. International Journal of Oncology, 2018, 52, 755-767.	3.3	15
25	Manfred Schmitt (1947â€“2018). Biological Chemistry, 2018, 399, 923-924.	2.5	0
26	Insights into the activity control of the kallikrein-related peptidase 6: small-molecule modulators and allosterism. Biological Chemistry, 2018, 399, 1073-1078.	2.5	5
27	Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach. Journal of Proteomics, 2018, 182, 12-20.	2.4	57
28	Kallikrein-related peptidase 7 overexpression in melanoma cells modulates cell adhesion leading to a malignant phenotype. Biological Chemistry, 2018, 399, 1099-1105.	2.5	10
29	Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patientsâ€™ prognosis. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1109-1118.	2.5	5
30	Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer. Scientific Reports, 2018, 8, 16861.	3.3	10
31	Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer. British Journal of Cancer, 2018, 119, 1-9.	6.4	27
32	Kallikreinâ€related peptidases are activators of the CC chemokine CCL14. European Journal of Immunology, 2018, 48, 1592-1594.	2.9	4
33	Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer. Expert Opinion on Therapeutic Targets, 2018, 22, 745-763.	3.4	22
34	Elevated tumor tissue protein expression levels of kallikrein-related peptidases KLK10 and KLK11 are associated with a better prognosis in advanced high-grade serous ovarian cancer patients. American Journal of Cancer Research, 2018, 8, 1856-1864.	1.4	6
35	Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer. Scientific Reports, 2017, 7, 2099.	3.3	33
36	Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer. Biological Chemistry, 2017, 398, 765-773.	2.5	13

#	Article	IF	Citations
37	Aberrant expression of kallikreinâ€related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion. Molecular Oncology, 2017, 11, 1330-1347.	4.6	14
38	Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer. Biological Chemistry, 2017, 398, 1151-1164.	2.5	17
39	The Predictive Value ofPITX2DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. Disease Markers, 2017, 2017, 1-14.	1.3	18
40	Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer. PLoS ONE, 2017, 12, e0186847.	2.5	24
41	Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis. American Journal of Cancer Research, 2017, 7, 1959-1970.	1.4	8
42	Pericellular regulation of prostate cancer expressed kallikrein-related peptidases and matrix metalloproteinases by cell surface serine proteases. American Journal of Cancer Research, 2017, 7, 2257-2274.	1.4	10
43	Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer. Biological Chemistry, 2016, 397, 1265-1276.	2.5	25
44	Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome. American Journal of Cancer Research, 2016, 6, 61-70.	1.4	5
45	STIM1/ORAI1-mediated Ca2+ Influx Regulates Enolase-1 Exteriorization. Journal of Biological Chemistry, 2015, 290, 11983-11999.	3.4	34
46	The first potent diphenyl phosphonate KLK4 inhibitors with unexpected binding kinetics. MedChemComm, 2015, 6, 1954-1958.	3.4	10
47	Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221. Oncotarget, 2015, 6, 8103-8114.	1.8	13
48	Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer. BioMed Research International, 2014, 2014, 1-9.	1.9	16
49	Clinical value of protein expression of kallikrein-related peptidase 7 (KLK7) in ovarian cancer. Biological Chemistry, 2014, 395, 95-107.	2.5	22
50	Kallikrein-related peptidase 7 (KLK7) is a proliferative factor that is aberrantly expressed in human colon cancer. Biological Chemistry, 2014, 395, 1075-1086.	2.5	32
51	Secretome and degradome profiling shows that Kallikreinâ€related peptidases 4, 5, 6, and 7 induce TGFÎ²â€1 signaling in ovarian cancer cells. Molecular Oncology, 2014, 8, 68-82.	4.6	51
52	Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 63-84.	6.1	24
53	A bioengineered 3D ovarian cancer model for the assessment ofÂpeptidaseâ€“mediated enhancement of spheroid growth andÂintraperitoneal spread. Biomaterials, 2013, 34, 7389-7400.	11.4	53
54	Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies. Thrombosis and Haemostasis, 2013, 110, 408-422.	3.4	29

#	Article	IF	Citations
55	Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. Radiology and Oncology, 2013, 47, 319-329.	1.7	38
56	Impact of expression of the uPA system in sarcomas. Biomarkers in Medicine, 2013, 7, 473-480.	1.4	7
57	Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biological Chemistry, 2012, 393, 391-401.	2.5	36
58	Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Gynecologic Oncology, 2012, 127, 569-578.	1.4	33
59	Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells. Molecular Cancer, 2012, 11, 62.	19.2	58
60	5 Cellular Model Systems to Study the Tumor Biological Role of Kallikrein-related Peptidases in Ovarian and Prostate Cancer. , 2012, , 83-110.		3
61	Interdependence of kallikrein-related peptidases in proteolytic networks. Biological Chemistry, 2010, 391, 581-587.	2.5	50
62	Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie, 2010, 92, 1546-1567.	2.6	129
63	Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer. Biological Chemistry, 2010, 391, 391-401.	2.5	35
64	Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Review of Molecular Diagnostics, 2010, 10, 1051-1067.	3.1	56
65	Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Review of Molecular Diagnostics, 2010, 10, 947-962.	3.1	43
66	Using kallikrein-related peptidases (KLK) as novel cancer biomarkers. Thrombosis and Haemostasis, 2009, 101, 222-224.	3.4	13
67	Using kallikrein-related peptidases (KLK) as novel cancer biomarkers. Thrombosis and Haemostasis, 2009, 101, 222-4.	3.4	8
68	Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Research and Treatment, 2008, 111, 229-240.	2.5	55
69	Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biological Chemistry, 2008, 389, 623-632.	2.5	72
70	Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. International Journal of Molecular Medicine, 2008, 21, 251-9.	4.0	27
71	Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biological Chemistry, 2006, 387, 217-22.	2.5	43
72	Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biological Chemistry, 2006, 387, 807-811.	2.5	79